Stay updated on IO102 Pembrolizumab in Metastatic NSCLC Clinical Trial
Sign up to get notified when there's something new on the IO102 Pembrolizumab in Metastatic NSCLC Clinical Trial page.

Latest updates to the IO102 Pembrolizumab in Metastatic NSCLC Clinical Trial page
- Check3 days agoChange DetectedThe page’s revision/version indicator was updated from v3.5.2 to v3.5.3.SummaryDifference0.0%

- Check10 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check17 days agoNo Change Detected
- Check39 days agoChange DetectedRevision history updated: added v3.5.0 and removed v3.4.3.SummaryDifference0.0%

- Check46 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check74 days agoChange DetectedRevision: v3.4.2 was added, and the prior government funding status notice (v3.4.1) was removed. The core study details and data remain unchanged.SummaryDifference0.4%

- Check82 days agoChange DetectedAdded a government funding/status notice and updated the site version from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to IO102 Pembrolizumab in Metastatic NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IO102 Pembrolizumab in Metastatic NSCLC Clinical Trial page.